单位:[1]Peking University People’s Hospital, Peking University Hepatology Institute, Beijing Key Laboratory for Hepatitis C and Immunotherapy for Liver Disease[2]Peking University People’s Hospital, Peking University Hepatology Institute, Beijing Key Laboratory for Hepatitis C and Immunotherapy for Liver Disease[3]The Sixth People`s Hospital of Zhengzhou[4]The Second Hospital of Nanjing[5]Shenyang Sixth People`s Hospital[6]Guangzhou Eighth People’s Hospital[7]Department of Infectious Diseases, Southwest Hospital, Third Military Medical University[8]Qingdao Municipal Hospital[9]Jinan City Infectious Diseases Hospital[10]Sixth People’s Hospital of Dalian[11]Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Translational Medicine in Liver Cirrhosis, National Clinical Research Center of Digestive Diseases, Beijing, China临床科室国家中心肝病分中心首都医科大学附属北京友谊医院[12]First Hospital of Jilin University[13]Beijing Youan Hospital, Capital Medical University[14]Affiliated Hospital of Yanbian[15]Beijing Kawin Technology Share-Holding Co., Ltd[16]Peking University Hepatology Institute, Peking University People’s Hospital
第一作者单位:[1]Peking University People’s Hospital, Peking University Hepatology Institute, Beijing Key Laboratory for Hepatitis C and Immunotherapy for Liver Disease
推荐引用方式(GB/T 7714):
Rao Huiying,Song Guangjun,Li Guangming,et al.Safety and Efficacy of Coblopasvir and Sofosbuvir in Genotype 1, 2, 3, and 6 HCV-Infected Patients with Compensated Cirrhosis or without Cirrhosis[J].HEPATOLOGY.2018,68:582A-583A.
APA:
Rao, Huiying,Song, Guangjun,Li, Guangming,Yang, Yongfeng,Wu, Xiaofeng...&Wei, Lai.(2018).Safety and Efficacy of Coblopasvir and Sofosbuvir in Genotype 1, 2, 3, and 6 HCV-Infected Patients with Compensated Cirrhosis or without Cirrhosis.HEPATOLOGY,68,
MLA:
Rao, Huiying,et al."Safety and Efficacy of Coblopasvir and Sofosbuvir in Genotype 1, 2, 3, and 6 HCV-Infected Patients with Compensated Cirrhosis or without Cirrhosis".HEPATOLOGY 68.(2018):582A-583A